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Abstract The specific contribution of risk or candidate
gene variants to the complex phenotype of schizophrenia is
largely unknown. Studying the effects of such variants on
brain function can provide insight into disease-associated
mechanisms on a neural systems level. Previous studies found
common variants in the complexin2 (CPLX2) gene to be
highly associated with cognitive dysfunction in schizophre-
nia patients. Similarly, cognitive functioning was found to be
impaired in Cplx2 gene-deficient mice if they were subjected
to maternal deprivation or mild brain trauma during puberty.
Here, we aimed to study seven common CPLX2 single-
nucleotide polymorphisms (SNPs) and their neurogenetic
risk mechanisms by investigating their relationship to a
schizophrenia-related functional neuroimaging intermediate
phenotype. We examined functional MRI and genotype data
collected from 104 patients with DSM-IV-diagnosed
schizophrenia and 122 healthy controls who participated in
the Mind Clinical Imaging Consortium study of schizophre-
nia. Seven SNPs distributed over the whole CPLX2 gene were
tested for association with working memory-elicited neural
activity in a frontoparietal neural network. Three CPLX2
SNPs were significantly associated with increased neural
activity in the dorsolateral prefrontal cortex and intraparietal
sulcus in the schizophrenia sample, but showed no associa-
tion in healthy controls. Since increased working memory-
related neural activity in individuals with or at risk for
schizophrenia has been interpreted as ‘neural inefficiency,’
these findings suggest that certain variants of CPLX2 may
contribute to impaired brain function in schizophrenia, pos-
sibly combined with other deleterious genetic variants,
adverse environmental events, or developmental insults.
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Introduction
The neurobiological underpinnings of severe mental dis-
orders such as schizophrenia are still poorly understood.
Twin studies suggest that certain genes predispose indi-
viduals to schizophrenia, but a concordance rate of
40–65 % in monozygotic twins [1, 2] indicates the
importance of epigenetic or environmental risk factors. The
widely accepted diathesis-stress model [3–5] proposes that
susceptibility to psychological disorders is due to a pre-
existing vulnerability that emerges after exposure to dele-
terious psychological states and environmental events. The
diathesis-stress conceptual model is the basis for the ‘two
(or second)-hit’ hypothesis of schizophrenia. First, descri-
bed by Bayer et al. [6], the two-hit hypothesis states that a
genetic defect leads to deficiencies in neuronal networks
(first hit), and a second hit (e.g., an environmental hazard)
further perturbs the functioning of the network, perhaps
through modulation of gene activity, which then leads to
the emergence of an ongoing psychotic illness.
Since there is considerable evidence for synaptic dys-
function playing a central role in the etiology of schizo-
phrenia [7, 8], synaptic molecules such as synapsins and
complexins might be of great importance for the disease
process. The complexin family of presynaptic regulatory
proteins consists of four members, of which only com-
plexin1 and complexin2 (CPLX2) are strongly expressed
in the central nervous system [9]. Complexins regulate
synaptic neurotransmitter release and thereby influence
synaptic signaling [10], synaptic plasticity [11], and
neuronal network function [12]. Dysregulation of com-
plexin expression occurs in neurodegenerative disorders
such as Huntington’s, Parkinson’s, and Alzheimer’s dis-
ease [13–15], as well as in psychiatric disorders such as
schizophrenia [16, 17]. Although results from case–con-
trol genetic association studies have been inconsistent
[18, 19], Eastwood and Harrison [20] found markedly
reduced CPLX2 expression in the dorsolateral prefrontal
cortex (DLPFC) and the superior temporal cortex (STC)
in schizophrenia patients.
Recent animal models allow us to better understand how
genetic and environmental risk factors for schizophrenia
interact [21]. Yamauchi et al. [22] examined the physio-
logical characteristics of Cplx2 gene-deficient mice sub-
jected to maternal deprivation stress and found a significant
decrease in posttetanic potentiation and LTP induction in
the knockout mice compared to the wild type, suggesting
that in the setting of an environmental insult (maternal
deprivation), variation in the Cplx2 gene becomes a critical
determinant of synaptic functioning. Radyushkin et al. [23]
designed a similar experimental approach for a schizo-
phrenia-like phenotype in mice to specifically test the
aforementioned ‘second-hit’ hypothesis. They studied
behavior and cognitive functioning (which is typically
impaired in schizophrenia) in Cplx2-null mutant
(Cplx2-/-) mice jointly with a mild parietal neurotrauma,
applied during puberty. Consistent with the ‘second-hit’
hypothesis, they found reduced prepulse inhibition and
deficits of spatial learning as well as decreased hippo-
campal volume in Cplx2-/- mice after the neurotrauma
had been applied, but not in lesioned wild-type mice or
nonlesioned Cplx2-/- mice.
Subsequently, Begemann et al. [24] tested for associa-
tions between CPLX2 single-nucleotide polymorphisms
(SNPs) and several domains of cognitive functioning
(executive functioning, reasoning, and verbal learning/
memory) in a large sample of patients with schizophrenia
(NSZ = 1,071). They found associations between six
CPLX2 SNPs and impaired neurocognitive performance in
patients. Assuming that schizophrenia patients have been
exposed to additional environmental risk, they interpreted
CPLX2 as a modifier of cognitive functioning in individ-
uals which were subjected to adverse environmental events
or developmental insults (‘second hit’). Although CPLX2
has not been shown to be a risk gene for a diagnosis of
schizophrenia in a recent GWA study/meta-analysis [25,
26], the results presented by Begemann et al. illustrate the
impact of CPLX2 risk variants on the severity of cognitive
dysfunction in patients with schizophrenia. However, the
precise roles of these variants in disease-associated mech-
anisms on a neural systems level are unknown. Impaired
working memory processing and functional abnormalities
of a lateral frontoparietal network, which mediates working
memory functions, are established intermediate phenotypes
of schizophrenia [27–29]. Therefore, the aim of our study
was to investigate the neurogenetic risk mechanisms of
CPLX2 SNPs by examining their associations with fron-
toparietal network efficiency during working memory.
Based on the aforementioned studies in rodents and in
patients with schizophrenia [24], we hypothesized the
presence of such associations in patients with schizophre-
nia, assuming that they have been exposed to additional
environmental risk factors.
Materials and methods
Participants
Imaging, genetic, and behavioral data from participants of
the multisite Mind Clinical Imaging Consortium (MCIC)
study of schizophrenia [30, 31] were used for analyses. All
subjects gave written informed consent prior to study
enrollment. The human subjects’ research committees at
each of the four sites (Massachusetts General Hospital
(MGH) and the Universities of Iowa (UI), Minnesota
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(UMN), and New Mexico (UNM)) approved the study
protocol. The patient group (SZ) consisted of subjects with
a DSM-IV diagnosis of schizophrenia established using
structured clinical interviews and review of case files by
trained clinicians (see also Online Resource 1.1). Healthy
controls (HC) were included if they had no history of a
medical or Axis I psychiatric diagnosis. All participants
were required to be at least 18 years of age and no older
than 60 and had to be fluent in English. Participants were
excluded if they had a history of neurologic disease, or
psychiatric disease other than schizophrenia, history of a
head injury with loss of consciousness, history of substance
abuse or dependence within the past month, severe or
disabling medical conditions, any contraindication to MR
scanning, or an IQ less than 70 (based on the reading
subtest from the Wide Range Achievement Test
(WRAT3)). For details on clinical measures, see Online
Resource 1.1.
Sternberg Item Recognition Paradigm
The Sternberg Item Recognition Paradigm (SIRP) is a
working memory (WM) task, previously shown to activate
the DLPFC in healthy controls and schizophrenia patients
[32]. The SIRP was administered during six 46 s blocks per
run for three 360 s runs. In each block, a memory set,
composed of one (load1), three (load3), or five (load5)
digits, was presented (two blocks per load condition). The
Encode phase was followed by a presentation of 14 digits,
one at a time (the Probe phase), and participants responded
to each probe to indicate whether or not the probe digit was
in the memory set. For additional details about the para-
digm, see Roffman et al. [33] and Online Resource 1.2. The
stimuli and responses were presented and collected using
E-prime software (EPrime v1.1, Psychology Software
Tools, Inc., Pittsburg, PA) during fMRI scanning. Partici-
pants were excluded from further analysis if they com-
pleted a block with less than a 80 % accuracy rate and/or
with more than 6 probes not answered within a block.
Image acquisition and processing
Structural MRI data were acquired with either a 1.5-T
Siemens Sonata (UNM, MGH, UI) or a 3-T Siemens Trio
(UMN) and analyzed in an automated manner with atlas-
based FreeSurfer parcellation and segmentation software
version 4.0.1 (http://surfer.nmr.mgh.harvard.edu) to gen-
erate cortical and subcortical volumetric measures of
regions of interest (ROIs) using each participant’s indi-
vidual anatomy [34]. We focused on two ROIs, the intra-
parietal sulcus (IPS), which is a standard output of
FreeSurfer parcellation, and the DLPFC. DLPFC ROIs
were derived from a combination of several FreeSurfer
cortical parcellations as described previously [35, 36]. For
details, see Online Resource 1.3.
Functional MRI data were acquired with either a 1.5-T
Siemens Sonata (UNM) or a 3-T Siemens Trio (UMN,
MGH, UI) and analyzed using the Function Biomedical
Informatics Research Network (FBIRN) Image Processing
Stream (FIPS), a pipeline using the Functional MRI of the
Brain (FMRIB) Software Library of FSL [37]. Variability
due to different scanners and acquisition protocols was
analyzed using ten MCIC subjects who were scanned at all
four sites [36]. Variability of neural activity due to site
differences was negligible small compared to variability
due to subject differences. For additional information about
data acquisition and processing, see Online Resource 1.3.
A functional imaging linear model [38] was fit to model
the Probe phases of each subject’s preprocessed functional
time series. We used the linear Contrasts of Parameter
Estimate (COPE) Probe-load 5 versus Probe-load 1 and
refer to responses to this condition as ‘load-dependent’
activation [33]. We obtained indices of activation for the
left and right IPS and left and right DLPFC ROIs using the
COPE obtained from the second-level fixed-effects ana-
lysis for each participant. We applied an additional func-
tional mask, based on the COPE of all loads (average of
Probe-load 1, Probe-load 3 and Probe-load 5) versus fixa-
tion exceeding a threshold of Z = 2.3 and extracted the
mean percentage signal change. The use of a functional
mask (within anatomical ROIs) from all working memory
loads protected against biases in signal change calculations
derived from individual conditions [39].
Genotyping and imputation
Blood samples were obtained from 255 MCIC participants
and sent to the Harvard Partners Center for Genetics and
Genomics for DNA extraction. All DNA extraction and
genotyping was done blind to group assignment. Geno-
typing was performed at the Mind Research Network
Neurogenetics Core Laboratory using the IlluminaHu-
manOmni-Quad BeadChip. Quality control steps included
common standard procedures [40] using PLINK, 1.07 [41].
SNPs on the X or Y chromosome, or those with a geno-
typing rate of less than 90 % or a minor allele frequency of
less than 5 % were excluded from the analysis. We
removed seven participants with extreme heterozygosity
values (±3SD). Another 22 subjects were excluded
because of low quality or missing fMRI data (for imaging
control steps, see Online Resource 1.3). The final sample
with complete and high-quality structural and functional
MRI and genetic data comprised of 122 HC and 104 SZ.
Additional SNPs were imputed based on the Hapmap3
data set. Imputation was done using IMPUTE2 [42] with a
probability threshold of 0.95. The imputed data set was
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then again filtered for a minor allele frequency of 5 %, a
genotyping rate of less than 90 %, and a Hardy–Weinberg
equilibrium in controls with a threshold of 10-6. Using this
data set, seven CPLX2 SNPs (rs2443541, rs2243404,
rs4242187, rs10072860, rs4868539, rs3892909, and
rs3822674) were extracted, five of those being significantly
associated with current cognition in patients with schizo-
phrenia in a recent candidate gene study [24]. General
information and quality control measures including details
about SNP location, an LD plot, and allele frequencies
according to diagnostic group for all seven SNPs are given
in Online Resource Table 1 and 2 and Online Resource
Fig. 1. Because of the low frequency of T/T genotypes for
both rs2243404 (N = 6) and rs2443541 (N = 6), T/T and
C/T participants were combined into a T allele carrier
group (N = 37 and N = 38, respectively).
Statistics and principal component analysis (PCA)
Given our strong hypothesis, we primarily analyzed the
patient sample (N = 104). Additional (separate) analyses
were carried out for the control group (N = 122). Basic
demographic characteristics were compared across geno-
type group and across sites with different scanner field
strengths using one-way ANOVA and subsequent Bonfer-
roni post hoc tests where necessary. Chi-square statistics
were used to examine differences in categorical variables.
Alpha was set to 0.05 for all analyses.
Each of the seven CPLX2 SNPs was tested for associ-
ation with neural activity in the a priori defined working
memory-related brain regions using a linear mixed model
and controlling for age, gender, and scanner field strength.
We assumed a compound symmetry covariance structure
for the load-dependent change of neural activity in the four
brain regions (DLPFC and IPS mean activity in the left and
right hemisphere). Population stratification was addressed
using ten principal components as additional covariates
calculated by EIGENSTRAT of the EIGENSOFT 3.0
software package [43, 44]. Details are given in Online
Resource 1.6. We ran separate mixed models for the two
diagnostic groups (SZ and HC). Mixed models for
rs2243404 and rs2443541 were performed contrasting C
allele homozygotes and T allele carriers, respectively,
because of the small number of participants in the TT
group. Multiple testing was addressed by Bonferroni cor-
rection (p \ 0.007; corrected for the number of tested
SNPs). All statistical analyses were carried out in IBM
SPSS Statistics 19.
To verify our results in an ethnically homogeneous
sample we re-ran the analyses in a subsample defined by
stringent genetic criteria, including individuals of European
descent only (NSZ = 68; NHC = 95; see Online Resource
1.7 for further details). Additional analyses were carried
out on a whole-brain level using FSL (FMRIB Software
Library; version 4.1.7; Smith et al. [37]). Please refer to
Online Resource 1.8 for methodological details.
Results
Sample characteristics
In the patient group, there were no differences among
genotype groups (seven CPLX2 SNPs) with respect to
gender, age, parental SES, handedness, length of illness,
and negative or positive symptoms. Rs3892909 T allele
homozygotes and rs4868539 A allele homozygotes showed
significantly higher WRAT3-RT scores; rs3892909 C allele
homozygotes had higher lifetime antipsychotic exposure;
and rs4242187 C/T heterozygotes showed a higher working
memory performance than C/C or T/T homozygotes (see
Online Resource 2.1, Online Resource Table 3). Also,
patients from acquisition sites with different scanner field
strengths did not differ in any demographic or clinical
variables. In the control group, there were no differences
among genotype groups for any of the tested variables
(data not shown). An overview about the demographic (and
clinical) variables of patients with schizophrenia and
healthy controls, respectively, is displayed in Table 1. As
expected, schizophrenia patients had a significantly lower
performance on the Sternberg Paradigm when compared to
healthy controls (F = 44.26; p \ 0.001).
Functional MRI
Three CPLX2 SNPs (rs2443541, rs2243404, and
rs4868539) were associated with load-dependent neural
activity in working memory-related brain regions (DLPFC
and IPS; see Fig. 1) in the schizophrenia sample. For both,
rs2443541 and rs2243404, C allele homozygotes showed
an increased neural activity when compared to T allele
carriers [F(df = 1,104) = 12.387, p = 0.001 and
F(df = 1,104) = 12.972, p \ 0.001, respectively]. The
same was found for rs4868539 G allele carriers compared
to A allele homozygotes [F(df = 2,104) = 5.530,
p = 0.005; see Table 2]. According to Bonferroni-cor-
rected post hoc tests, the estimated residuals of the neural
activity differed significantly between G allele homozy-
gotes and A allele homozygotes (p = 0.024), as well as
between heterozygotes and A allele homozygotes
(p = 0.005), but not between G allele homozygotes and
heterozygotes. We found no evidence for associations
between working memory-related neural activity and any
of the seven CPLX2 SNPs in healthy participants. Table 3
displays the test statistics and p values for the linear mixed
models of each SNP. For CPLX2 rs2443541 and
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rs2243404, the aforementioned effects were also deter-
minable on a whole-brain level (see Online Resource 2.2).
In a subsample of participants of European descent, we
found similar results for rs2443541 and rs2243404 in
schizophrenia patients. Again, none of the tested poly-
morphisms showed any association with neural activity in
the DLPFC or IPS in the subsample of healthy participants
with European ancestry (Table 3). In subsequent models,
we also covaried for the amount of lifetime antipsychotic
exposure, working memory performance, and WRAT3-RT
scores. All main effects remained robust (Online Resource
2.3, Online Resource Table 4).
Discussion
Our analysis revealed an association between CPLX2
polymorphisms and working memory load-dependent
neural activity in a frontoparietal brain network in
schizophrenia patients but not in healthy controls. Results
were strengthened by subsequent analyses including
potentially confounding variables such as lifetime anti-
psychotic exposure and working memory performance.
Our findings are in line with the results from Cplx2-/-
rodent models and consistent with the ‘second-hit’
hypothesis of schizophrenia, i.e., CPLX2 risk variants
increase neural inefficiency if the individual has experi-
enced an additional risk factor. Second-hit risk factors such
as prenatal infections, perinatal complications, early insults
to the brain, stressful life events, or drug abuse are more
prevalent in people affected by schizophrenia than demo-
graphically similar control samples (for a review, see Vi-
lain et al. [45]).
The risk alleles of two (rs2443541 and rs2243404;
C allele for both SNPs) out of the three genetic variants
which were associated with working memory-related
neural activity in our study had previously been related to
cognitive functioning specifically in schizophrenia
patients [24]. As described in the Supplementary Online
Fig. 1 FreeSurfer cortical parcellation of the DLPFC and IPS in the
schizophrenia sample. Cortical statistical map illustrating regions of
working memory-related load-dependent neural activity in the
dorsolateral prefrontal cortex (anterior outline) and the intraparietal
sulcus (posterior outline) in the schizophrenia sample. This map is
shown on the inflated surface of the standard average subject allowing
visualization of data across the entire cortical surface without
interference from cortical folding
Table 2 Associations between working memory-related load-dependent neural activity and CPLX2 SNPs in schizophrenia patients
rs2443541 rs2243404 rs4242187 rs10072860
CC T carrier CC T carrier CC CT TT GG GT TT
N 67 37 67 37 43 47 14 30 55 19
Left DLPFC 0.072 0.043 0.072 0.042 0.062 0.063 0.055 0.084 0.053 0.049
Right DLPFC 0.069 20.024 0.069 20.028 0.063 0.033 -0.047 0.027 0.024 0.078
Left IPS 0.087 0.044 0.087 0.043 0.077 0.077 0.035 0.076 0.068 0.072
Right IPS 0.058 0.030 0.057 0.030 0.049 0.050 0.035 0.044 0.046 0.059
rs4868539 rs3892909 rs3822674
GG AG AA CC CT TT CC CT TT
N 20 44 40 19 44 41 25 45 34
Left DLPFC 0.085 0.068 20.003 0.072 0.070 0.047 0.056 0.050 0.080
Right DLPFC 0.044 0.068 20.054 0.025 0.068 0.003 0.004 0.049 0.039
Left IPS 0.076 0.076 0.053 0.067 0.083 0.061 0.086 0.077 0.053
Right IPS 0.044 0.058 0.035 0.049 0.063 0.033 0.051 0.053 0.038
Working memory-related mean neural activity (% BOLD change) for corresponding genotype groups of each CPLX2 SNP in the schizophrenia
sample; significant differences according to the linear mixed models (p \ 0.007; Bonferroni corrected for number of tested SNPs) are printed in
bold face. DLPFC dorsolateral prefrontal cortex, IPS intraparietal sulcus. N = number of schizophrenia patients carrying the particular genotype
142 Eur Arch Psychiatry Clin Neurosci (2015) 265:137–145
123
content of Begemann et al. (eFigure 1A), for both SNPs, T
homozygotes performed significantly better compared to
C allele carriers regarding executive functioning and
verbal learning/memory, which is in line with our results.
Increased load-dependent neural activity in a frontopari-
etal network in individuals with CPLX2 risk variants can
be interpreted as ‘neural inefficiency,’ i.e., the additional
recruitment of neural resources to achieve a comparable
task performance as nonrisk carriers or healthy controls
[32, 46, 47]. Based on similar findings in unaffected
siblings, prodromal, and medication-naı¨ve and first-epi-
sode patients with schizophrenia, ‘neural inefficiency’
during working memory has been proposed to reflect an
expression of genetic liability to schizophrenia [48–53]. A
meta-analysis showed that working memory-related neu-
ral networks are consistently ‘disrupted’ in schizophrenia
[54]. It has been hypothesized that this putative neural
signature of schizophrenia may arise from altered signal
transduction and synaptic functioning and plasticity [28,
55]. Synaptic proteins that are involved in the presynaptic
secretory machinery such as complexions appear possible
molecular candidates.
According to the Expression Atlas of EMBL-EBI
(http://www.ebi.ac.uk/gxa/; last accessed on 2013-03-15),
CPLX2 is primarily expressed in the human brain, but in
the DLPFC and STC of schizophrenia patients, CPLX2
expression is abnormally reduced [20]. The altered
expression profile of CPLX2 and other synaptic proteins in
schizophrenia suggests that there are aberrations in the
precise organization and functioning of neural circuits,
indicating that CPLX2 polymorphisms may contribute
susceptibility to schizophrenia [19, 20]. Results of the
current study provide a link between frontoparietal cortical
function in schizophrenia and variation in the CPLX2 gene
in schizophrenia.
The effects of CPLX2 are different from common risk
genes of schizophrenia since CPLX2 seems to moderate the
expression of the disease but not the general risk for
schizophrenia. Other possible explanations for the case-
only effect described here include gene X gene and gene X
genome interactions. A variety of environmental and other
factors can alter the influence of mutant alleles on organ-
ismal phenotypes, and the impact of these factors can vary
with genetic background [56]. All explanations have in
common that CPLX2 is not an independent risk factor for
schizophrenia.
The findings of this study should be interpreted in light
of the following limitations. First, we focused on seven
CPLX2 SNPs that had been previously investigated by
other researchers. These SNPs may be in high linkage
disequilibrium with other functional variants that are
responsible for the effects described above. Second, we had
an only medium-sized and rather heterogeneous sample,
but subsequent models in European ancestry subsamples of
patients and controls confirmed our initial results. Fur-
thermore, results of additional whole-brain analyses sup-
port our main findings and the assumption that the
observed SNP effects are rather specific to working
memory-related brain regions. Third, we did not measure
environmental factors in this study; we based our hypoth-
esis on previous studies that have consistently shown a
significantly higher prevalence of a variety of pre-, peri-
and postnatal environmental risk factors for patients with
schizophrenia compared to healthy subjects [57–59], which
may represent a ‘second hit.’ Finally, although we covaried
for the amount of lifetime antipsychotic exposure in a
secondary model and found our results to be essentially the
same, we cannot completely exclude a potential effect of
antipsychotic medication on our results in patients with
schizophrenia. Sawada et al. [60] studied the effect of
Table 3 Test statistics and p values for the mixed models testing associations between CPLX2 variants and load-dependent working memory-
related neural activity in schizophrenia patients and healthy controls
SNP SZ SZ (Europ. descent) HC HC (Europ. descent)
F df p F df p F df p F df p
rs2443541 12.387* 1, 104 0.001 5.278 1, 68 0.025 1.233 1, 122 0.269 3.127 1, 95 0.080
rs2243404 12.972* 1, 104 <0.001 5.349 1, 68 0.024 1.454 1, 122 0.230 3.274 1, 95 0.074
rs4242187 2.327 2, 104 0.103 0.535 2, 68 0.588 0.426 2, 122 0.654 1.380 2, 95 0.257
rs10072860 0.849 2, 104 0.431 0.802 2, 68 0.453 1.095 2, 122 0.338 2.212 2, 95 0.115
rs4868539 5.530* 2, 104 0.005 1.638 2, 68 0.202 1.241 2, 122 0.293 1.981 2, 95 0.144
rs3892909 1.890 2, 103 0.156 2.388 2, 67 0.100 0.007 2, 122 0.993 0.201 2, 95 0.819
rs3822674 0.410 2, 104 0.665 0.012 2, 68 0.988 0.024 2, 122 0.976 0.661 2, 95 0.519
Single-locus association analyses of working memory-related load-dependent neural activity (left and right DLPFC and left and right IPS) using
mixed models and covarying for age, gender, scanner field strength, and population stratification. Significant test statistics and p values are
displayed in bold face (p \ 0.05) indicating differences between the genotype groups of each SNP. * p value survives Bonferroni correction
(p \ 0.007; corrected for number of tested SNPs). Additional models were carried out in healthy controls and in a subset of each participants
group of European descent. SNP = single-nucleotide polymorphism; SZ = patient with schizophrenia; HC = healthy control
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antipsychotic drug treatment on the expression of com-
plexin and other presynaptic proteins in rats and observed
no differences between treated and control animals for
either Cplx1 or Cplx2 immunostaining in frontal cortex.
Taken together, our results indicate that CPLX2 may be
involved in the etiology of schizophrenia and we identified
one of its potential biological mechanisms by studying the
effects of CPLX2 risk variants on working memory load-
dependent neural activity in a frontoparietal network. Since
the reported associations were restricted to the patient
group, we interpret them in the framework of the ‘second-
hit’ hypothesis and assume that certain CPLX2 variants
only confer risk for schizophrenia if other risk factors are
also present. Although not directly related to the risk of the
disorder, CPLX2 variants may moderate its expression. Our
findings may help to understand the heterogeneity of
schizophrenia and its underlying complex genetic archi-
tecture. However, additional studies are needed to replicate
the findings and to fully untangle the effects of such genetic
variants on brain function.
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